This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
A radioisotope thermoelectric generator (RTG, RITEG), or radioisotope power system (RPS), is a type of nuclear battery that uses an array of thermocouples to convert the heat released by the decay of a suitable radioactive material into electricity by the Seebeck effect. This type of generator has no moving parts and is ideal for deployment in remote and harsh environments for extended periods with no risk of parts wearing out or malfunctioning. RTGs are usually the most desirable power source for unmaintained situations that need a few hundred watts (or less) of power for durations too long for fuel cells, batteries, or generators to provide economically, and in places where solar cells are not practical. RTGs have been used as power sources in satellites, space probes, and uncrewed remote facilities such as a series of lighthouses built by the Soviet Union inside the Arctic Circle. Safe use of RTGs requires containment of the radioisotopes long after the productive life of the unit. The expense of RTGs tends to limit their use to niche applications in rare or special situations.
== External links == Engineered Pathogens and Unnatural Biological Weapons: The Future Threat of Synthetic Biology . Threats and considerations Synthetic biology books popular science book and textbooks Introductory Summary of Synthetic Biology Archived 2018-04-02 at the Wayback Machine. Concise overview of synthetic biology concepts, developments and applications Collaborative overview article on Synthetic Biology Controversial DNA startup wants to let customers create creatures (2015-01-03), San Francisco Chronicle It's Alive, But Is It Life: Synthetic Biology and the Future of Creation (28 September 2016), World Science Festival
== See also == The FASTQ format, used to represent DNA sequencer reads along with quality scores. The SAM and CRAM formats, used to represent genome sequencer reads that have been aligned to genome sequences. The GVF format (Genome Variation Format), an extension based on the GFF3 format.
Competition with analogs For releasing the His-tagged protein from the carrier, a compound is used that has a structure similar to the His-tag and which also forms a coordination complex with the immobilized metal ions. Such a compound added to the His-tagged protein on the carrier competes with the protein for the immobilized metal ions. The compound added at high concentration replaces virtually all carrier-bound protein which is thus eluted from the carrier. Imidazole is the side chain of histidine and is typically used at a concentration of 100 - 500 mM for elution. Histidine can also be used.
=== Pregnancy and breastfeeding === Hypothyroidism is common among pregnant women. A nationwide cohort study showed that 1.39% of all pregnant women in 2010 in Denmark received a prescription of levothyroxine during pregnancy. According to the U.S. Food and Drug Administration pregnancy categories, levothyroxine has been assigned category A. Given that no increased risk of congenital abnormalities has been demonstrated in pregnant women taking levothyroxine, therapy should be continued during pregnancy. Furthermore, treatment should be immediately administered to women diagnosed with hypothyroidism during pregnancy, as hypothyroidism is associated with a higher rate of complications, such as spontaneous abortion, preeclampsia, and premature birth. Thyroid hormone requirements increase during and last throughout pregnancy. As such, pregnant women are recommended to increase to nine doses of levothyroxine each week, rather than the usual seven, as soon as their pregnancy is confirmed. Repeat thyroid function tests should be done five weeks after the dosage is increased. While a minimal amount of thyroid hormones is found in breast milk, the amount does not influence infant plasma thyroid levels. Furthermore, levothyroxine was not found to cause any adverse events to the infant or mother during breastfeeding. Since adequate thyroid hormone concentrations are required to maintain normal lactation, appropriate levothyroxine doses should be administered during breastfeeding.
Sources: en.wikipedia.org
Trepanging is the act of collecting or harvesting sea cucumbers (Indonesian: trepang, Malay: těripang) that are used as food. The collector, or fisher, of trepang is a trepanger. Trepanging is comparable to clamming, crabbing, lobstering, musseling, shrimping and other forms of "fishing" whose goal is the acquisition of edible invertebrates rather than fish.
==== 2010 kimchi ingredient price crisis ==== Due to heavy rainfall shortening the harvesting time for cabbage and other main ingredients for kimchi in 2010, the price of kimchi ingredients and kimchi itself rose greatly. Korean and international newspapers described the rise in prices as a national crisis. Some restaurants stopped offering kimchi as a free side dish, which The New York Times compared to an American hamburger restaurant no longer offering free ketchup. In response to the kimchi price crisis, the South Korean government announced the temporary reduction of tariffs on imported cabbage to coincide with the kimjang season.
To describe the types of protein–protein interactions (PPIs), proteins can interact in a "transient" way (to produce some specific effect in a short time, like signal transduction) or to interact with other proteins in a "stable" way to form complexes that become molecular machines within the living systems. A protein complex assembly can result in the formation of homo-oligomeric or hetero-oligomeric complexes. In addition to the conventional complexes, as enzyme-inhibitor and antibody-antigen, interactions can also be established between domain-domain and domain-peptide. Another important distinction to identify protein–protein interactions is the way they have been determined, since there are techniques that measure direct physical interactions between protein pairs, named "binary" methods, while there are other techniques that measure physical interactions among groups of proteins, without pairwise determination of protein partners, named "co-complex" methods.
WHO suggests assessing workers' exposure in workplaces with methods similar to those used for the proposed specific occupational exposure limit (OEL) value of the MNM (conditional recommendation, low-quality evidence). Because there are no specific regulatory OEL values for MNMs in workplaces, WHO suggests assessing whether workplace exposure exceeds a proposed OEL value for the MNM. A list of proposed OEL values is provided in an annex of the guidelines. The chosen OEL should be at least as protective as a legally mandated OEL for the bulk form of the material (conditional recommendation, low-quality evidence). If specific OELs for MNMs are not available in workplaces, WHO suggests a step-wise approach for inhalation exposure with, first an assessment of the potential for exposure; second, conducting basic exposure assessment and third, conducting a comprehensive exposure assessment such as those proposed by the Organisation for Economic Cooperation and Development (OECD) or Comité Européen de Normalisation (the European Committee for Standardization, CEN) (conditional recommendation, moderate quality evidence). For dermal exposure assessment, WHO found that there was insufficient evidence to recommend one method of dermal exposure assessment over another. C. Control exposure to MNMs
Horning (1917–2020), American biochemist and pioneer of chromatography who developed new techniques for studying drug metabolism Benjamin Hsiao (born 1958), Taiwanese American chemist working to understand the structural, morphological development and manipulation of complex polymer systems Linda Hsieh-Wilson (PhD 1996), American chemist known for work in chemical neurobiology on understanding the structure and function of carbohydrates in the nervous system Heinrich Hubert Maria Josef Houben (1875–1940), German organic chemist known for work on ketone synthesis, terpenes, and camphor Coenraad Johannes van Houten (1801–1887), Dutch chemist and chocolate maker who invented cocoa powder Amir H. Hoveyda (PhD 1986), American chemist, particularly noted for developing catalysts for stereoselective olefin metathesis Marcia Huber (PhD 1985), American chemical engineer known for modeling the thermophysical properties of fluids Robert Huber (born 1937), German chemist known for crystallizing an intramembrane protein important in photosynthesis, 1988 Nobel Prize in chemistry Catherine T. Hunt (born 1955), American chemist who worked on nuclear magnetic resonance and became president of the American Chemical Society
Sources: en.wikipedia.org
The epithelium is the innermost layer. It is where most digestive, absorptive and secretory processes occur. The lamina propria, the underlying layer of loose connective tissue within the mucosa. The muscularis mucosae, a thin layer of smooth muscle. The epithelium, the most exposed part of the mucosa, is a glandular epithelium with many goblet cells. Goblet cells secrete mucus, which lubricates the passage of food along and protects the intestinal wall from digestive enzymes. In the small intestine, villi are folds of the mucosa that increase the surface area of the intestine. The villi contain a lacteal, a vessel connected to the lymph system that aids in the removal of lipids and tissue fluids. Microvilli are present on the epithelium of a villus and further increase the surface area over which absorption can take place. Numerous intestinal glands as pocket-like invaginations are present in the underlying tissue. In the large intestines, villi are absent and a flat surface with thousands of glands is observed. Underlying the epithelium is the lamina propria, which contains myofibroblasts, blood vessels, nerves, and several different immune cells, and the muscularis mucosa which is a layer of smooth muscle that aids in the action of continued peristalsis and catastalsis along the gut.
== Signs and symptoms == The clinical findings in all three CCDs result from the consequences of decreased levels of creatine in tissues where it is required. In affected individuals with any of the three disorders, there is an almost complete absence of creatine and phosphocreatine in the brain. The two tissues with the highest demands for creatine are the brain and skeletal muscles. Muscular findings usually include weakness and decreased endurance. Other clinical findings include seizures, intellectual disability and developmental delay. Most affected individuals appear normal at birth, with clinical findings becoming apparent during the first year of life, and progressing.
Mariusz Zbigniew Pudzianowski (Polish pronunciation: [ˈmarjuʂ pudʑaˈnɔfskʲi]; born 7 February 1977), also known as 'Pudzian' and 'Dominator', is a Polish former strongman and mixed martial artist. With 43 international titles at a record 70% win percentage, 58 total wins, 71 podiums and 28 world records in his strongman career. During his career as a strongman, Pudzianowski won five World's Strongest Man titles in 2002, 2003, 2005, 2007 and 2008, the most in the 48 year history of the competition. He also won two runner-up titles in 2006 and 2009 and made 9 out of 9 appearances into the World's Strongest Man final (a feat replicated only by Hafþór Júlíus Björnsson since then). While securing eight World Strongman Cup Federation wins and twelve Strongman Super Series wins, he also won the Europe's Strongest Man title a record six times and the Poland's Strongest Man title a record seven times. In 2009, Pudzianowski started his career as a mixed martial artist. By 2022, he had won his 17th professional fight.
== Development and evolution == The formation of rete pegs (often referred to as rete ridges in developmental biology) is driven by an evolutionary and molecular mechanism entirely distinct from the development of other skin appendages like hair follicles and sweat glands. In mammals, the evolutionary acquisition of epidermal rete ridges closely coincides with the loss of fur density. It is proposed that mammals replaced the genetic program for forming discrete microscopic appendages with a distinct program that creates this interconnected appendage network. During morphogenesis, the development of rete pegs requires significant signaling interactions between epidermal and dermal cells. Specifically, the broad epidermal activation of bone morphogenetic protein (BMP) signaling is required to organize the ridge networks around the underlying dermal pockets. While mature scar tissue in adults typically lacks rete pegs (making it more prone to shearing), recent studies in neonatal mammals, such as pigs, demonstrate that these epidermal structures can regenerate de novo during early wound healing.
A 2018 systematic review and network meta-analysis of 50 trials involving 12 different psychosocial interventions for amphetamine, methamphetamine, or cocaine addiction found that combination therapy with both contingency management and community reinforcement approach had the highest efficacy (i.e., abstinence rate) and acceptability (i.e., lowest dropout rate). Other treatment modalities examined in the analysis included monotherapy with contingency management or community reinforcement approach, cognitive behavioral therapy, 12-step programs, non-contingent reward-based therapies, psychodynamic therapy, and other combination therapies involving these. As of December 2019, there is no effective pharmacotherapy for methamphetamine addiction. A systematic review and meta-analysis from 2019 assessed the efficacy of 17 different pharmacotherapies used in randomized controlled trials (RCTs) for amphetamine and methamphetamine addiction; it found only low-strength evidence that methylphenidate might reduce amphetamine or methamphetamine self-administration. There was low-to moderate-strength evidence of no benefit for most of the other medications used in RCTs, which included antidepressants (bupropion, mirtazapine, sertraline), antipsychotics (aripiprazole), anticonvulsants (topiramate, baclofen, gabapentin), naltrexone, varenicline, citicoline, ondansetron, prometa, riluzole, atomoxetine, dextroamphetamine, and modafinil. Medication-Assisted Treatment (MAT) combines FDA-approved medications with behavioral therapies to address substance use disorders.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.